These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 35779568)

  • 1. Future therapies for cystic fibrosis.
    Wilson C
    Lancet Respir Med; 2022 Aug; 10(8):e75-e76. PubMed ID: 35779568
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacologic approaches to correcting the basic defect in cystic fibrosis.
    Lukacs GL; Durie PR
    N Engl J Med; 2003 Oct; 349(15):1401-4. PubMed ID: 14534332
    [No Abstract]   [Full Text] [Related]  

  • 3. Gentamicin in pharmacogenetic approach to treatment of cystic fibrosis.
    Hamilton JW
    Lancet; 2001 Dec; 358(9298):2014-6. PubMed ID: 11755605
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical trial research in focus: ensuring new cystic fibrosis drugs fulfil their potential.
    Elborn JS; Davies J
    Lancet Respir Med; 2017 Sep; 5(9):681-683. PubMed ID: 28853396
    [No Abstract]   [Full Text] [Related]  

  • 5. Novel pharmacologic therapies for cystic fibrosis.
    Zeitlin PL
    J Clin Invest; 1999 Feb; 103(4):447-52. PubMed ID: 10021451
    [No Abstract]   [Full Text] [Related]  

  • 6. Cystic fibrosis transmembrane conductance regulator biomarkers in 'real life': can we evaluate individual efficacy of cystic fibrosis transmembrane conductance regulator therapy?
    van Koningsbruggen-Rietschel S; Naehrlich L
    Ther Adv Respir Dis; 2015 Aug; 9(4):198-200. PubMed ID: 26175480
    [No Abstract]   [Full Text] [Related]  

  • 7. A Review on the Use of Cystic Fibrosis Transmembrane Conductance Regulator Gene Modulators in Pediatric Patients.
    Bitonti M; Fritts L; So TY
    J Pediatr Health Care; 2019; 33(3):356-364. PubMed ID: 31029283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First cystic fibrosis drug advances towards approval.
    Sheridan C
    Nat Biotechnol; 2011 Jun; 29(6):465-6. PubMed ID: 21654649
    [No Abstract]   [Full Text] [Related]  

  • 9. Cystic fibrosis: ironing out the problem of infection?
    Reid DW; Anderson GJ; Lamont IL
    Am J Physiol Lung Cell Mol Physiol; 2008 Jul; 295(1):L23-4. PubMed ID: 18487353
    [No Abstract]   [Full Text] [Related]  

  • 10. Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors.
    Solomon GM; Marshall SG; Ramsey BW; Rowe SM
    Pediatr Pulmonol; 2015 Oct; 50 Suppl 40(0 40):S3-S13. PubMed ID: 26097168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AJRCCM: 100-Year Anniversary. Progress along the Pathway of Discovery Leading to Treatment and Cure of Cystic Fibrosis.
    Ramsey BW; Welsh MJ
    Am J Respir Crit Care Med; 2017 May; 195(9):1092-1099. PubMed ID: 28459323
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacogenetics of cystic fibrosis treatment.
    Carter SC; McKone EF
    Pharmacogenomics; 2016 Aug; 17(13):1453-63. PubMed ID: 27490265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug bests cystic-fibrosis mutation.
    Ledford H
    Nature; 2012 Feb; 482(7384):145. PubMed ID: 22318583
    [No Abstract]   [Full Text] [Related]  

  • 14. How do cystic fibrosis transmembrane conductance regulator mutations produce lung disease?
    Pilewski JM; Frizzell RA
    Curr Opin Pulm Med; 1995 Nov; 1(6):435-43. PubMed ID: 9363079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the basic defect in cystic fibrosis.
    Welsh MJ
    N Engl J Med; 2010 Nov; 363(21):2056-7. PubMed ID: 21083391
    [No Abstract]   [Full Text] [Related]  

  • 16. Improving complex medical care while awaiting next-generation CFTR potentiators and correctors: The current pipeline of therapeutics.
    Goralski JL; Davis SD
    Pediatr Pulmonol; 2015 Oct; 50 Suppl 40():S66-73. PubMed ID: 26335956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rescuing protein conformation: prospects for pharmacological therapy in cystic fibrosis.
    Gelman MS; Kopito RR
    J Clin Invest; 2002 Dec; 110(11):1591-7. PubMed ID: 12464661
    [No Abstract]   [Full Text] [Related]  

  • 18. Therapeutic pipeline for individuals with cystic fibrosis with mutations nonresponsive to current cystic fibrosis transmembrane conductance regulator modulators.
    Fajac I; Sermet-Gaudelus I
    Curr Opin Pulm Med; 2021 Nov; 27(6):567-574. PubMed ID: 34494979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CFTR mutations and cystic fibrosis.
    Prescrire Int; 2013 Oct; 22(142):232. PubMed ID: 24298580
    [No Abstract]   [Full Text] [Related]  

  • 20. Cystic fibrosis lung disease: interplay of a microbial microcosm and extremes of inflammation.
    Blau H
    Isr Med Assoc J; 2006 Jan; 8(1):58-9. PubMed ID: 16450756
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.